Business
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York. Details of Dr. Mendelsohn’s presentation are a
About this update from Vivani Medical, Inc.
[{"type":"image","alt":"Vivani Medical, Inc.","displaySize":"","headline":null,"caption":"Vivani Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/c23870f4ae46a8fd33cfe7a0a48ef637"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aU1HV9H8XgPgL8OdypT.mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c23870f4ae46a8fd33cfe7a0a48ef637","width":300,"height":300}},"lazy":false},{"type":"text","content":"ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York.","length":453,"tagName":"p"},{"type":"text","content":"Details of Dr. Mendelsohn’s presentation are as follows:","length":56,"tagName":"p"},{"type":"text","content":"Date: Wednesday, September 10, 2025Time: 1:00 PM - 1:30 pm, Eastern TimeLocation: Lotte New York Palace Hotel, Holmes I - 4th Floor","length":133,"tagName":"p"},{"type":"text","content":"Dr. Mendelsohn will highlight Vivani’s portfolio of miniature, ultra long-acting drug implants, powered by its proprietary NanoPortal™ drug implant technology. These innovative implants are designed to address poor medication adherence and improve patient outcomes in chronic disease management. The Company is prioritizing the advancement of NPM-139, a novel semaglutide implant, with clinical development expected to begin in 2026, pending regulatory clearance.","length":463,"tagName":"p"},{"type":"text","content":"More information about the H.C. Wainwright 27th Annual Global Investment Conference can be found at https://hcwevents.com/annualconference/.","length":145,"tagName":"p"},{"type":"text","content":"About Vivani Medical, Inc.","length":26,"tagName":"p"},{"type":"text","content":"Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient to...